|Day Low/High||88.88 / 89.64|
|52 Wk Low/High||74.97 / 96.31|
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.
We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?
Tech giants, Big Pharma and insurers are all angling to profit from the $3 trillion-plus U.S. healthcare market.
Britain's largest pharmaceuticals company reports growth in its HIV medicines business as it submits a shingles vaccine for FDA approval.
The U.K. currency falls to its lowest intra-day level since the Oct. 7 'flash crash' before testimony from Bank of England Governor Mark Carney.
The chip maker sinks on news of production problems and a gloomy fourth-quarter prognosis.
The group's blood cancer drug Gleevec also holds up better than expected against generic competition.
Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.
Novartis stock has fallen 14% in the last year. A wave of generic drugs has wrecked results.
Shares in the stock decline only marginally as the pharmaceuticals group sticks with its full-year forecast.
Wall Street sells off as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season and crude oil retreats from highs.
Stock losses accelerate on Tuesday afternoon as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season.
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
A KeyBanc Capital Markets analyst increases his price target on the stock to $221 from $199.
Here are Friday's top research calls, including upgrades for Casey's and Qualcomm and downgrades for AutoZone and Mylan.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CPHD, KODK, PINC, SRLP Downgrades: APU, ATU, AZO, BDL, GATX, GRA, HLT, MYL, NVS, TI.A, VG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Here's a technical look at how to trade some of the biggest stocks on Wall Street.
Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.
Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.
The company's share price despite reporting better-than-expected earnings and revenue and
Stocks retreat from record highs on Monday as a selloff in health care overshadows a rally in energy.
Stocks pull slightly lower on Monday as a selloff in health care squares off against a rally in energy.
Novartis (NVS) is developing a new asthma pill that demonstrated promising results in a small clinical trial.
Stocks pull lower on Monday morning as a selloff in health care sours the jobs-inspired rally that pushed benchmark indices to record highs last week.
TheStreet highlights 3 stocks pushing the drugs industry lower today.
The Swiss pharmaceuticals company confirms a forecast for full-year sales to increase in the low to mid-single digits, and for earnings per share to grow faster than revenue.
Shares of the global healthcare company, Novartis, are down after it saw its profits fall in the second quarter.
Novartis (NVS) stock is lower in pre-market trading on Tuesday after cautioning that full-year profit could slide on more investments in its heart-failure drug.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.